Clarity Pharmaceuticals Ltd has released a press release.
Copper-67 SAR-bisPSMA updates
Filed with ASX ·
6ix hasn’t read this filing yet.
Clarity Pharmaceuticals Ltd. on 6ix
Story so far
Earlier from Clarity Pharmaceuticals
- Positive guidance from the US FDA on Phase III trial
- Michelle Parker Promoted to CEO
- Shareholder briefing - presentation
- SECuRE trial advances
- S&P DJI Announces September 2024 Quarterly Rebalance
Later from Clarity Pharmaceuticals
- Clarity and Nucleus RadioPharma sign MSA
- Head-to-head IIT with SAR-bisPSMA
- Chairperson Address AGM
- First 2 participants dosed with Cu-64 SAR-bisPSMA in Co-PSMA
- Last patient assessment completed for SARTATE trial
Follow Clarity Pharmaceuticals into a list and get an email when it puts out news.
Follow Clarity Pharmaceuticals